The facts indicated that miR‐21‐5p may promote melanoma cell proliferation and cell‐cycle progression via down‐regulating CDKN2C. Of course, some limitations appeared in our study, including the relevant results in vivo, miR‐21‐5p/CDKN2C‐mediated downstream signaling pathway and the clinical significance of miR‐21‐5p/CDKN2C in patients with melanoma, which will be further explored in the next work. This evidence concerns the gene CDKN2C and melanoma.